Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $5.50.
MGNX has been the topic of a number of analyst reports. Barclays increased their price target on MacroGenics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Monday, April 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of MacroGenics in a report on Friday, May 8th. Finally, B. Riley Financial upgraded MacroGenics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $3.00 to $9.00 in a report on Friday, April 10th.
Check Out Our Latest Research Report on MacroGenics
Institutional Trading of MacroGenics
Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in MacroGenics by 64.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 755,245 shares of the biopharmaceutical company's stock worth $1,269,000 after acquiring an additional 295,108 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in MacroGenics in the fourth quarter valued at approximately $2,964,000. GSA Capital Partners LLP increased its stake in MacroGenics by 740.5% in the fourth quarter. GSA Capital Partners LLP now owns 511,004 shares of the biopharmaceutical company's stock valued at $823,000 after purchasing an additional 450,203 shares in the last quarter. Armistice Capital LLC raised its holdings in MacroGenics by 6.1% in the fourth quarter. Armistice Capital LLC now owns 6,324,000 shares of the biopharmaceutical company's stock worth $10,182,000 after purchasing an additional 364,000 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in MacroGenics in the second quarter worth $28,000. 96.89% of the stock is owned by institutional investors.
MacroGenics Price Performance
MGNX opened at $3.69 on Monday. The company has a market cap of $234.54 million, a price-to-earnings ratio of -3.35 and a beta of 1.20. The firm has a 50 day simple moving average of $4.27 and a 200 day simple moving average of $3.24. MacroGenics has a fifty-two week low of $1.29 and a fifty-two week high of $5.08.
MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.01). MacroGenics had a negative net margin of 44.79% and a negative return on equity of 147.80%. The business had revenue of $20.77 million during the quarter, compared to the consensus estimate of $15.24 million. As a group, analysts expect that MacroGenics will post -1.76 EPS for the current year.
About MacroGenics
(
Get Free Report)
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.
Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MacroGenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.
While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
